All In Biotech

Drug Trial Radar · NCT05507450

Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)

A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) in Healthy Adults

Last checked: Nov 19, 2026Latest source record: May 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 1,271 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,271

Actual

Start

Sep 7, 2022

Primary completion

Jun 5, 2023

Study completion May 7, 2024

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Aug 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to compare the dengue virus-neutralizing antibody geometric mean titers (GMTs) for each of the 4 dengue serotypes (DENV1, DENV2, DENV3, and DENV4) at Day 28 post-vaccination for participants administered the V181 Low-Potency Level vaccine versus the V181 Mid-Potency Level vaccine. This study will also evaluate the safety and tolerability of 3 different V181 potency level vaccines. The primary hypothesis of the study is that the V181 Low-Potency Level vaccine is non-inferior to the V181 Mid-Potency Level vaccine for each of the 4 dengue serotypes based on GMTs at Day 28 post-vaccination.

Conditions

  • Dengue Disease
  • Dengue Virus

Interventions

  • V181 High-Potency LevelBiological

    0.5 mL SC dose of V181 High-Potency vaccine

  • V181 Mid-Potency LevelBiological

    0.5 mL SC dose of V181 Mid-Potency vaccine

  • V181 Low-Potency LevelBiological

    0.5 mL SC dose of V181 Low-Potency vaccine

  • PlaceboBiological

    0.5 mL SC dose of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dengue Virus-Neutralizing Antibody Titers, as Measured by Virus Reduction Neutralization Test (VRNT)Time frame: Day 28 post-vaccination
  2. Percentage of Participants With Vaccine-Related Serious Adverse Events (SAEs)Time frame: Up to 28 days post-vaccination

Locations

32 sites in 7 countries. Site status is shown where the registry gives one.

  • California Research Foundation ( Site 0114)

    San Diego, California

  • Advanced Medical Research Institute ( Site 0115)

    Miami, Florida

  • Rochester Clinical Research, Inc. ( Site 0122)

    Rochester, New York

  • University of Texas Medical Branch ( Site 0113)

    Galveston, Texas

  • IMA Clinical Research San Antonio ( Site 0111)

    San Antonio, Texas

  • Alliance for Multispecialty Research LLC (AMR - Norfolk) ( Site 0123)

    Norfolk, Virginia

  • Paratus Clinical Research Western Sydney ( Site 0007)

    Blacktown, New South Wales, Australia

  • Emeritus Research ( Site 0010)

    Botany, New South Wales, Australia

  • USC Clinical Trials Moreton Bay ( Site 0001)

    Morayfield, Queensland, Australia

  • USC Clinical Trials Sunshine Coast ( Site 0005)

    Sippy Downs, Queensland, Australia

  • USC Clinical Trials Brisbane (South Bank) ( Site 0006)

    South Brisbane, Queensland, Australia

  • Emeritus Research ( Site 0009)

    Camberwell, Victoria, Australia

  • Diex Recherche Quebec Inc. ( Site 0022)

    Québec, Quebec, Canada

  • Diex Recherche Joliette ( Site 0023)

    Saint-Charles-Borromée, Quebec, Canada

  • Diex Recherche Sherbrooke Inc. ( Site 0024)

    Sherbrooke, Quebec, Canada

  • Diex Recherche Victoriavile Inc. ( Site 0021)

    Victoriaville, Quebec, Canada

  • FVR, Kokkolan rokotetutkimusklinikka ( Site 0037)

    Kokkola, Keski-Pohjanmaa, Finland

  • FVR, Oulun rokotetutkimusklinikka ( Site 0032)

    Oulu, North Ostrobothnia, Finland

  • FVR, Tampereen rokotetutkimusklinikka ( Site 0039)

    Tampere, Pirkanmaa, Finland

  • FVR, Porin rokotetutkimusklinikka ( Site 0033)

    Pori, Satakunta, Finland

  • FVR, Seinäjoen rokotetutkimusklinikka ( Site 0040)

    Seinäjoki, South Ostrobothnia, Finland

  • FVR, Turun rokotetutkimusklinikka ( Site 0031)

    Turku, Southwest Finland, Finland

  • FVR, Espoon rokotetutkimusklinikka ( Site 0036)

    Espoo, Uusimaa, Finland

  • FVR, Etelä-Helsingin rokotetutkimusklinikka ( Site 0038)

    Helsinki, Uusimaa, Finland

  • FVR, Itä-Helsingin rokotetutkimusklinikka ( Site 0035)

    Helsinki, Uusimaa, Finland

  • Berliner Centrum für Reise- und Tropenmedizin ( Site 0043)

    Berlin, Germany

  • Bernhard Nocht Institute for Tropical Medicine ( Site 0041)

    Hamburg, Germany

  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen-Division of Infectious Diseases and Tropical (

    München, Bavaria, Germany

  • Rambam Health Care Campus-Oncology ( Site 0053)

    Haifa, Israel

  • Hadassah Medical Center-Clinical Reaserch Unit ( Site 0052)

    Jerusalem, Israel

  • Sheba Medical Center-Early Phase Clinical Trials Unit ( Site 0051)

    Ramat Gan, Israel

  • Kaohsiung Medical University Hospital-Infectious diseases Division, Department of Internal Medicine

    Kaohsiung City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.